Immunotech Biopharm (HKSE:06978) Total Assets : HK$774.81 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Total Assets?

Immunotech Biopharm's Total Assets for the quarter that ended in Jun. 2024 was HK$774.81 Mil.

During the past 12 months, Immunotech Biopharm's average Total Assets Growth Rate was -26.70% per year. During the past 3 years, the average Total Assets Growth Rate was 19.20% per year. During the past 5 years, the average Total Assets Growth Rate was 54.20% per year.

During the past 7 years, Immunotech Biopharm's highest 3-Year average Total Assets Growth Rate was 96.80%. The lowest was 19.20%. And the median was 81.30%.

Total Assets is connected with ROA %. Immunotech Biopharm's annualized ROA % for the quarter that ended in Jun. 2024 was -23.43%. Total Assets is also linked to Revenue through Asset Turnover. Immunotech Biopharm's Asset Turnover for the quarter that ended in Jun. 2024 was 0.00.

Immunotech Biopharm Total Assets Historical Data

The historical data trend for Immunotech Biopharm's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm Total Assets Chart

Immunotech Biopharm Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

1,434.65

1,344.08

982.08

925.65

602.21

Immunotech Biopharm Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Assets	Get a 7-Day Free Trial								982.08	1,135.12	925.65	774.81	602.21

Immunotech Biopharm Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Immunotech Biopharm's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	186.916	+	738.732
	=	925.65

Immunotech Biopharm's Total Assets for the quarter that ended in Jun. 2024 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2024 )	+	Total Liabilities (Q: Jun. 2024 )
	=	84.33	+	690.479
	=	774.81

Immunotech Biopharm (HKSE:06978) Total Assets Explanation

Total Assets is connected with ROA %.

Immunotech Biopharm's annualized ROA % for the quarter that ended in Jun. 2024 is

ROA %	=	Net Income (Q: Jun. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
	=	-199.192	/	( (925.648	+	774.809)	/ 2 )
	=	-199.192	/	850.2285
	=	-23.43 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Immunotech Biopharm's Asset Turnover for the quarter that ended in Jun. 2024 is

	Asset Turnover
=	Revenue (Q: Jun. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Jun. 2024 ))	/ count )
=	0	/	( (925.648	+	774.809)	/ 2 )
=	0	/	850.2285
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Immunotech Biopharm Total Assets Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunotech Biopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176

Website

https://www.eaal.net

Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.

Executives

Jung Hyun Chul
Evodevo Ltd
Yan Kaijing	2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Cao Longxiang	2201 Interest of corporation controlled by you
Cao Fei	2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si	2501 Other
Yan Xijun	2501 Other
Wu Naifeng	2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited	2501 Other
Li Yunhui	2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
China Resources Company Limited	2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines